VAV1 and myelodysplastic syndrome: We recently demonstrated that mice expressing C-terminal-truncated ASXL1aa1−587 (pan-hematopoietic Vav1 promoter-driven Asxl1Y588X transgenic mice) developed various myeloid malignancies (i.e., AML, MPN, MDS, and MDS/MPN) [75].